New COVID-19 drug candidate passes first safety check in healthy volunteers
NCT ID NCT07518771
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new drug called PA-001 in 47 healthy and elderly volunteers. Participants received either PA-001 or a placebo through an IV. The main goal was to see if the drug causes any side effects and to understand how the body processes it. This information will help decide the right doses for future studies in people with COVID-19.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PA-001
What this could lead to
If successful, this could help determine safe doses for future studies of PA-001 as a potential treatment for COVID-19.
What could go wrong
This is an early Phase 1 safety study in healthy people, not patients. It does not test if PA-001 actually works against COVID-19, and many early-stage drugs fail to show benefit later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit Inc.
Dallas, Texas, 75230, United States